FDA, Industry Experts Highlight Key Regulatory Changes at DCAT Week ’16

What are the major regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and what is the business impact for pharmaceutical companies and their suppliers?

From changes relating to starting materials, to topical GMP inspection concerns, such as data integrity, to the upcoming re-authorization of the Generic Drug User Fee Amendments (GDUFA), the DCAT Week ’16 education program, GDUFA II and GMP API Inspection Trends: The Business Impact of Upcoming Regulatory Changes,  provides insight from leading industry and regulatory experts on what should be on your radar.

The program, which will be held Tuesday March 15 from 1:00 to 3:30 PM, will feature a business impact debrief, provided by Frances Zipp, President & CEO, Lachman Consultants, who will provide a global regulatory debriefing on key recent and upcoming regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and the pharmaceutical manufacturing value chain.

Plus, the US Food and Drug Administration (FDA) will provide a topical trend analysis for GMP inspections trends. Gain first-hand knowledge for the crucial issues drawing the attention of the agency in its inspection efforts in areas such as quality risk management, data integrity, and other concerns impacting API manufacturing.

In light of these issues, what are best practices that pharmaceutical companies, contract manufacturers, and suppliers can adapt to optimize external development and manufacturing? Robin Kumoluyi, Vice President & Global Head, Quality, Third Party Operations, Novartis Pharmaceuticals Corporation, offers perspective on best practices in supplier management and supplier oversight to help address these challenges.

Another key regulatory development ongoing in 2016 and coming to fruition in 2017 is the reauthorization of GDUFA. GDUFA is due for reauthorization in September 2017, and negotiations for GDUFA II are already underway. What has worked, what needs to be improved, and what changes may be on the horizon? Terri Nataline, J.D., Principal Consultant, Regulatory Practice, Lachman Consultants, provides the latest developments and what may be expected.

For information on this program, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

What’s Trending Inside the CDMO/CMO Market?

By
What are key trends shaping the market for bio/pharmaceutical outsourcing? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO sector in small-molecules, biologics, and drug products.

US Bio/Pharma Market: Is Stronger Growth Ahead?

By
The US bio/pharma market showed positive signs in 2023, despite a decline in spending on COVID-19 vaccines and products. Overall, the US market grew by 2.3% last year, and by 9.9%, excluding COVID-19 products. What’s projected in the near term?

AI Front and Center for Supply Chain Management 

By
How will artificial intelligence (AI) shape sourcing and supply chain management? A newly released study by DCAT and a panel discussion at DCAT Week examined AI’s potential, the types of projects and activities for which AI may be applied, and its challenges to its use and adoption.

The CDMO/CMO Report: Injectable Drugs

By
Demand for fill–finish capacity and sterile manufacturing is high, led by bio/pharma companies’ product portfolios and development pipelines in biologics and other key products, such as GLP-1 drugs. A roundup of the latest expansions by CDMOs/CMOs.